Report
EUR 12.77 For Business Accounts Only

Thanks to a better fundamental star rating, SAREPTA THERAPEUTICS sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to SAREPTA THERAPEUTICS (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date February 11, 2022, the closing price was USD 80.23 and its expected value was estimated at USD 75.80.
Underlying
Sarepta Therapeutics Inc.

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of diseases. The company is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies, Mucopolysaccharidosis type IIIA and other neuromuscular and central nervous system. The company's commercial product, EXONDYS 51? (eteplirsen) Injection is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch